Planep治疗高血压效果如何？

(Planep) can be used alone or in combination with other antihypertensive drugs for the treatment of hypertension. The clinical trial included 499 patients with grade 1 or 2 hypertension to analyze the effect of enalapril or eplerenone (Planep) in treating hypertension. Patients were randomized to receive treatment with enalapril or eplerenone (Planep).

A comparative study on the efficacy and tolerability of 499 patients with grade 1 or 2 hypertension who were randomized to receive enalapril or eplerenone (Planep) showed that at 6 months, enalapril was as effective as eplerenone (Planep) in reducing blood pressure. Systolic blood pressure (eplerenone (Planep) decreased by 14.5 mmHg; enalapril decreased by 12.7 mmHg: P = 0.199) and diastolic blood pressure (eplerenone (Planep) decreased by 11.2 mmHg; enalapril decreased by 11.3 mm Hg; P=0.910). After 12 months, the two groups were also similar (eplerenone (Planep) -16.5/-13.3mmHg; enalapril -14.8/-14.1mmHg, P values ​​0.251 and 0.331 respectively). Dropout due to adverse events (7.9% for eplerenone (Planep) and 9.3% for enalapril at 6 months) and treatment failure rates were also equal (23.3% for eplerenone (Planep) and 22.8% for enalapril at 6 months). About 2/3 of the patients in each group achieved normal blood pressure at 6 months with the above single treatment. In the eplerenone (Planep) group, the reduction in blood pressure was independent of renin levels, unlike enalapril. Both groups could reduce proteinuria above normal levels, but the eplerenone (Planep) group was more significant (-61.5% vs -25.7%; P=0.01). 

Subgroup analysis of the study showed that the effect of eplerenone (Planep) on reducing overall mortality was more obvious in patients with hypertension. Not only that, eplerenone (Planep) can improve the quality of life of patients with left ventricular dysfunction (ejection fraction ≤ 40%). Clinical trials have proven that (Planep) can also be used for congestive heart failure after acute myocardial infarction.